This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Neumune

Harbor BioSciences, Inc.

Drug Names(s): HE2100

Description: Neumune is an injectable formulation of 5-androstenediol that acts as an Immune Regulating Hormone (IRH). The goal of IRH therapy is to direct, through controlling gene expression, the production of key cytokines and enzymes that re-regulate immune and metabolic functions toward homeostasis. Other data on Neumune’s mechanism of action showed that the compound acts on a number of important stem cell components and stimulates production of white blood cells and platelets.


Neumune News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug